Juvenile idiopathic arthritis: An update on clinical and therapeutic approaches

Annali Italiani di Medicina Interna

Volumn 20, Issue 4, 2005, Pages 211-217

  Quarta, Laura ^a   Corrado, Addolorata ^a   Melillo, Nadia ^a   Cantatore, Francesco Paolo ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Diagnosis; Juvenile idiopathic arthritis; Juvenile rheumatoid arthritis; Therapy; Tumor necrosis factor

Indexed keywords

ADOLESCENT; CHILD; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; REVIEW;

ADOLESCENT; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; HUMANS;

EID: 33745581724     PISSN: 03939340     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Kulas DT, Schanberg L. Juvenile idiopathic arthritis. Curr Opin Rheumatol 2001;13:392-8.
2. White PH. Clinical features. Juvenile chronic arthritis. In: Klippel JH, Dieppe PA, eds. Rheumatology. Vol 2. 2nd ed. London: Mosby, 2000:18. 1-18. 10.
3. Guillame S, Prieur AM, Coste J, et al. Long-term outcome and proanosis in oligoarticular-onset juvenile idiopathic arthritis. Arthritis Rheum 2000;43:1858-65.
4. Sharma S, Sherry DD. Joint distribution at presentation in children with pauciarticular arthritis. J Pediatr 1999;134:642-3.
5. Manners P, Lesslie J, Speldewinde D, Tunbridge D. Classification of juvenile idiopathic arthritis: should family history be included in the criteria? J Rheumatol 2003;30:1857-63.
6. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998;25:1991-4.
7. Wood PH. Nomenclature and classification of arthritis in children. In: Munthe E, ed. The care of rheumatic children. Basel: European League Against Rheumatism, 1978:47-50.
8. Krumrey-Langkammerer M, Hafner R. Evaluation of the ILAR criteria for juvenile idiopathic arthritis. J Rheumatol 2001;28:2544-7.
9. Merino R, De Inocencio, Garcia-Consuegra J. Evaluation of ILAR classification criteria for juvenile idiopathic arthritis in Spanish children. J Rheumatol 2002;29:2731-6.
10. Manners PJ. Nomenclature and classification of juvenile idiopathic arthritis: where to after Durban? Modern Rheumatology 2000;10:68-77.
11. Murray K, Thompson SD, Glass DN. Pathogenesis of juvenile chronic arthritis: genetic and environmental factors. Arch Dis Child 1997;77:530-4.
12. Albani S. Etiology and pathogenesis. In: Klippel JH, Dieppe PA, eds. Rheumatology. Vol 2. 2nd ed. London: Mosby, 2000:20. 1-20.5.
13. Grom AA, Giannini EH, Glass DN. Juvenile rheumatoid arthritis and the trimolecular complex (HLA, T cell receptor and antigen). Arthritis Rheum 1994;37:601-7.
14. Ou LS, See LC, Wu CJ, Kao CC, Lin YL, Huang JL. Association between serum inflammatory cytokines and disease activity in juvenile idiopathic arthritis. Clin Rheumatol 2002;21:52-6.
15. Rooney M, David J, Symons J, Di Giovine F, Varsani H, Woo P. Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol 1995;34:454-60.
16. Bechtold S, Ripperger P, Muhlbayer D, et al. GH therapy in juvenile chronic arthritis: results of a two-year controlled study on growth and bone. J Clin Endocrinol Metab 2001;86:5737-44.
17. Bechtold S, Ripperger P, Hafner R, Said E, Schwarz P. Growth hormone improves height in patients with juvenile idiopathic arthritis: 4-year data of a controlled study. J Pediatr 2003;143:512-9.
18. Allen RC, Jimenez M, Cowell CT. Insulin-like growth factor and growth hormone secretion in juvenile chronic arthritis. Ann Rheum Dis 1991;50:602-6.
19. Green H, Morikawa M, Nixon T. A dual effector theory of growth-hormone action. Differentiation 1985;29:195-8.
20. Olney RC, Mougey EB. Expression of the components of the insulin-like growth factor axis across the growth-plate. Mol Cell Endocrinol 1999;156:63-71.
21. Jux C, Leiber K, Hugel U, et al. Dexamethasone impairs growth hormone (GH)-stimulated growth by suppression of local insulinlike growth factor (IGF)-I production and expression of GH-and IGF-I-receptor in cultured rat chondrocytes. Endocrinology 1998;139:3296-305.
22. Bergard PL, Schwarzenberg SJ, Humbcrt JT, et al. Inhibition of growth hormone action in models of inflammation. Am J Physiol Cell Physiol 2000;279: C1906-C1917.
23. Davies UM, Jones J, Reeve J, et al. Juvenile rheumatoid arthritis: effects of disease activity and recombinant human growth on insulin-like growth factor l, insulin-like growth factor binding proteins 1 and 3 and osteocalcin. Arthritis Rheum 1997;40:332-40.
24. Reeve J, Loftus J, Heps R, Ansell BM, Wrightd J, Woo PM. Biochemical prediction of changes in spinal bone mass in juvenile chronic (or rheumatoid) arthritis treated with glucocorticoids. J Rheumatol 1993;20:1189-95.
25. Allen DB, Golderg BD. Stimulation of collagen synthesis and linear growth by growth hormone in glucocorticoid-treated children. Pediatrics 1992;89:416-21.
26. Simon D, Lucidarme N, Prieur AM, Ruiz JC, Czernichow P. Effects on growth and body composition of growth hormone treatment in children with juvenile idiopathic arthritis requiring steroid therapy. J Rheumatol 2003;30:2492-9.
27. Avcin T, Cimaz R, Falcini F, et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2002;61:608-11.
28. Rossum VM, Soesbergen RV, De Kort S, et al. Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. J Rheumatol 2003;30:825-8.
29. Hromadnikova I, Vavrincova P, Stechova K, Hridelovs D. Antikeratin antibodies in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol 2001;19:470-3.
30. Kocher MS, Zurakowski D, Kasser JR. Differentiating between septic arthritis and transient synovitis of the hip in children: an evidence-based clinical prediction algorithm. J Bone Joint Surg Am 1999;81:1662-70.
31. Sauer ST, Farrell E, Geller E, Pizzutillo PD. Septic arthritis in a patient with juvenile rheumatoid arthritis. Clin Orthop 2004;418:219-21.
32. Kunnamo I, Pelkonen P. Routine analysis of synovial fluid cells is of value in the differential diagnosis of arthritis in children. J Rheumatol 1989;13:1076-80.
33. Ansell BM. Rheumatic disease mimics in childhood. Curr Opin Rheumatol 2000;12:445-7.
34. Frossard E, Rutti B, Burgherr J, et al. Detection of Borrelia DNA in synovial fluid for diagnosis of Lyme arthritis. Schweiz Med Wochenschr 1999;129:979-84.
35. Taylor-Robinson D, Keat A. How can a casual role for small bacteria in chronic inflammatory arthritides be established or refuted? Ann Rheum Dis 2001;60:177-84.
36. Priolo F. Malattie costituzionali dcllc ossa. Difetti congeniti. Sindromi malformative. In: Imaging osteo-articolare. CPA Edizioni, 2001:378-406.
37. Falcini F, Bardare M, Cimaz R, Lippi A, Corona F. Arthritis as a presenting feature of non-Hodgkin's lymphoma. Arch Dis Child 1998;78:367-70.
38. Evans TI, Nercessian BM, Sanders KM. Leukemic arthritis. Semin Arthritis Rheum 1994;24:48-56.
39. Robertson LP, Hickling P. Chronic recurrent multifocal osteomyelitis is a differential diagnosis of juvenile idiopathic arthritis. Ann Rheum Dis 2001;60:828-31.
40. Prieur AM. Management. Juvenile chronic arthritis. In: Klippel JH, Dieppe PA, eds. Rheumatology. Vol 2. 2nd ed. London: Mosby, 2000:21. 1-21.9.
41. Manteiro De Castro TC, Terreri MT, Len C, Esteves Hilaria MO. Treatment of refractory juvenile idiopathic arthritis via pulse therapy using methylprcdnisolone and cyclophosphamide. Sao Paulo Med J 2003;121:117-20.
42. Ramanan AV, Whitworth P, Baildam EM. Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child 2003;88:197-200.
43. Wallace CA. The use of methotrexate in childhood rheumatic disease. Arthritis Rheum 1998;41:381-91.
44. Kietz DA, Pepmueller PH, Moore TL. Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 2002;61:171-3.
45. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9.
46. Nam MH, Reda D, Boujoukos AJ, Suffredini AF. Recombinant human dimeric tumor necrosis factor (TNF) receptor (TNF:Fc): safety and pharmacokinetics in humans [abstract]. Clin Res 1993;41:249A.
47. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003;62:245-7.
48. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9.
49. Dekker L, Armbrust W, Rademaker CM, Prakker B, Kuis W, Wulffraat NM. Safety of anti-TNFα therapy in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2004;22:252-8.
50. Hyams JS, Markowithz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000;137:192-6.
51. Leer JH, Slifman NR, Gcrshon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-70.
52. Martinez ON, Noiseux RC, Martin CJ, Lara GV, Maranon GH. Reactivation tuberculosis in a patient with anti-TNFa therapy. Am J Gastroenterol 2001;96:1665-6.
53. Ferraccilli GF, Assaloni R, Perin A. Drug-induced systemic lupus erythematosus and anti-TNFa blockers. Lancet 2002;360:645-6.